Organogenesis (NASDAQ:ORGO) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Organogenesis (NASDAQ:ORGO) released its earnings results on Tuesday. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11, Zacks reports. The company had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same quarter in the previous year, the company posted $0.02 earnings per share. Organogenesis updated its FY 2024 guidance to EPS.

Organogenesis Trading Down 4.0 %

NASDAQ:ORGO traded down $0.16 during mid-day trading on Friday, hitting $3.85. The company had a trading volume of 238,428 shares, compared to its average volume of 823,152. The firm has a market cap of $510.43 million, a P/E ratio of -63.50 and a beta of 1.60. Organogenesis has a fifty-two week low of $2.16 and a fifty-two week high of $4.70. The business’s fifty day moving average is $2.97 and its two-hundred day moving average is $2.81. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.42 and a current ratio of 3.09.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.